Altimmune (NASDAQ:ALT) inks an agreement with Rockville, MD-based CDMO Vigene Biosciences to manufacture its single-dose intranasal COVID-19 vaccine candidate AdCOVID.
The company is in talks with additional partners aimed at producing at least 100M doses next year.
A Phase 1 clinical trial in healthy volunteers should launch in Q4.
Shares up 3% premarket on light volume.
